chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Discharging Provider:  MD PCP:  DO   Admission Duration: 8/10/2023 to 08/12/2023  Discharging to:  LTC HOSPITAL COURSE: Presenting Problem List:  Pneumonia due to COVID-19 virus [U07.1, J12.82] COVID-19 [U07.1]   Discharge Problem List: Active Hospital Problems   Diagnosis Date Noted POA ? COVID-19 08/10/2023 Yes   Resolved Hospital Problems No resolved problems to display.   Hospital Course:   Acute COVID-19: Two days of symptoms at facility, this includes persistent new cough, fatigue, confusion, possibly diarrhea.  Patient was on room air throughout his admission.  CXR without evidence of pneumonia.  No respiratory distress. No leukocytosis noted and lower concern for bacterial superimposed infection.  Patient received 3 days of remdesivir and discharged with Tessalon PRN and guaifenesin for some mild cough   Acute Weakness:  Normally can ambulate with walker, with COVID much weaker and needed hoyer lift last the night prior to admission. PT/OT evaluated and recommended SNF, CM arrange for patient to return to long-term Care with continued isolation precautions, this facility does not offer subacute rehab level of care but they plan to add home health care
patient felt like throat was swollen while walking around. he was able to stand, talk and breathe without difficulties. monitored patient while paramedic arrived. paramedic did a scan of the patient and offered to take him to hospital for follow up but patient denied going with them
exp sharp chest pain during physical exertion;gen chest discomfort for 3 days p/vax while sleeping;preventricular contractions began & cont intermittently;now irrespective of abstaining from caffeine consumption
Hives, swelling, ascites, blisters, non stop itch, pruritus,  puffy eyes, eyelid bump infection, dry skin
Vaccinated pt (per self report) admitted to inpatient facility. No information available on type, date, lot, or manufacturer details.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: PATIENT RECEIVED MODERNA COVID-19 VACCINE AND IMMUNIZER DESCRIBED HIM AS WANTING TO FAINT OR HAVING A SLIGHT SEIZURE.  THE PATIENT WAS RESPONSIVE AND HE DID KNOW HIS DATE OF BIRTH AND TODAY'S DATE.  PATIENT DID SAY HE HADN'T EATEN ALL DAY OR ATE A LIGHT SNACK ALL DAY.  WE CALLED THE AMBULANCE AND THEY SAID IT COULD OF BEEN DUE TO LOW BLOOD SUGAR OR MAYBE HIS BLOOD PRESSURE DROPPED.  WHEN THEY CHECKED HIS BLOOD PRESSURE HE HAD PERFECT BLOOD PRESSURE.
She was light headed. After sitting down she got a tingle in her throat and her chest got tight after that. Symptoms went away after 9pm the same day of vaccine
Around 7 pm on the 1/15/2021, I began to have a rash around the injection site.  It was minor. By the afternoon of 1/16/2021, I had a rash - small raised bumps - down both arms.  By the morning of 1/17/2021, the rash covered my entire body.  Hives developed everywhere clothes touched securely. (Bra area, collar of shirt/dress, waistline, ankles/feet).  I began taking an extra antihistamine/Claritin.  The rash itched intensely, and caused a feeling of radiating pain. By 1/20/2021, I began feeling a fullness in my throat, and had some vocal production issues.  When I tried to sing, my voice would cut out.  I sounded airy in my speech and singing.   1/21/2021 - mid-morning I called the Dr.'s Office and asked to be placed on their cancelation list for earliest appointment.  I was getting worried because the rash was worse and my throat was beginning to swell enough to be scary.  It did not feel like asthma.
Janssen COVID-19 Vaccine EUA I?ve been having heart palpitations on and off since receiving the vaccine. I never had them this frequently before getting the vaccine. Now, I experience them daily in small bouts.
12 Days after the second dose i started breaking out in hives body wide. They have gotten progressively worse to the point that at times i cannot walk/bend at full capacity or have to leave work early. I?m taking Prednisone, Claritin (4x 24hr tablet) and Benadryl to partially control symptoms. I will be applying fo the Xolair shot at the 6 week mark since the OTC medications are not working effectively.
DID NOT COMPLETE VIVOTIF PRIOR TO TRAVELING TO THE ENDEMIC AREA; This spontaneous case report (PVX2019-2798) was received from a pharmacist on 12-Nov-2019. It described a 33-year-old female consumer who "did not complete Vivotif prior to traveling to the endemic area" (PT: Inappropriate schedule of product administration), while being on oral Vivotif for typhoid fever.  Case report: The consumer took first dose of Vivotif on 11-Nov-2019 and would traveling to the endemic area on 13-Oct-2019.  Action taken with Vivotif with respect to reported event was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event "did not complete Vivotif prior to traveling to the endemic area" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "did not complete Vivotif prior to traveling to the endemic area" was considered as not applicable.
DTap number 3.  My son developed a fever of 104 Degrees F.  He started feeling constipated and nauseated. He had convulsions for 15 seconds. followed by hot and cold flashes.  We gave him fever reducer, fever decreased, still monitoring him.
increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22; an increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22/the vaccine induced hyperglycemia; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE INCREASED (increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22) and HYPERGLYCAEMIA (an increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22/the vaccine induced hyperglycemia) in a 71-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     Concurrent medical conditions included Type 2 diabetes mellitus.    On 13-Dec-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 13-Dec-2022, the patient experienced BLOOD GLUCOSE INCREASED (increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22) and HYPERGLYCAEMIA (an increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22/the vaccine induced hyperglycemia). At the time of the report, BLOOD GLUCOSE INCREASED (increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22) and HYPERGLYCAEMIA (an increased blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22/the vaccine induced hyperglycemia) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Dec-2022, Blood glucose: blood glucose level in 300s - daily - since administration of 2nd booster on 12/13/22.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medicine were reported. No treatment medicine were reported.   Most recent FOLLOW-UP information incorporated above includes: On 20-Dec-2022: Significant follow-up received and additional reporter and contains new event.
Information has been received on 06-JUN-2018 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 17-NOV-2009, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 14-NOV-2011, the patient was treated at a medical care facility for a persistent and severe vesicular rash, which was diagnosed as shingles. The patient has been prescribed VALTREX to manage her painful symptoms. As a direct and proximate result of the ZOSTAVAX and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient has suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Develops cold feeling throughout body ad tingling sensation in throat. Denies SOB or trouble swallowing. Given benadryl 25mg PO x 1.  Discharged home with family under stable condition.  SPO2 97% RA HR 95 RR 14 even and unlabored
Rapid heart beat, heart flutter,  spent 5 hours in the emergency room treating the heart fluttering, swelling in mouth, between upper nose and lip, numbness on left side of upper lip
Within 5 minutes of receiving vaccine, I developed a sharp chemical taste in my mouth.  This lasted for 1 - 1.5 hours.  Approx. 0300 on 19 Mar, I developed a 100f fever, with severe headache  and chills.  Fever and chills persisted until 20 Mar 2021 at approx 1530.  Headache continued until 22 Mar 2021.  It did diminish in severity after 20 Mar though, dropping from a 7 (on the 1-10 pain scale) to a 3.
Patient presented to the ED and was subsequently hospitalized for chronic alcoholism/alcohol withdrawal within 6 weeks of receiving covid vaccination.
Breakthrough covid case. Patient presented to ER on 6/22/22 with c/o of runny nose, congestion, sore throat, ear pain and myalgia. Hx of Moderna vaccine x 2 doses. DC home.
nausea; Rashes all over the body/Rashes on lower back/Rashes on legs; Itchiness; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (nausea), RASH (Rashes all over the body/Rashes on lower back/Rashes on legs) and PRURITUS (Itchiness) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 015M20A and 001A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced NAUSEA (nausea), RASH (Rashes all over the body/Rashes on lower back/Rashes on legs) and PRURITUS (Itchiness). The patient was treated with DIPHENHYDRAMINE, PARACETAMOL, PHENYLPROPANOLAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE;PARACETAMOL;PHENYLPROPANOLAMINE HYDROCHLORIDE]) ongoing since an unknown date at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL ITCH) ongoing since an unknown date at an unspecified dose and frequency and HYDROCORTISONE ACETATE ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, NAUSEA (nausea), RASH (Rashes all over the body/Rashes on lower back/Rashes on legs) and PRURITUS (Itchiness) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant product use was reported  Action taken with mRNA-1273 was not applicable
Information has been received from a physician for a of GARDASIL a pregnancy registry product, concerning a 17 year old female with convulsion who in approximately July 2009, was vaccinated with the second dose of GARDASIL (Lot # unknown). Concomitant therapy included DEPAKOTE. The physician reported that the patient had received the second dose of GARDASIL. In late May 2010, the patient became pregnant and subsequently, at 8 weeks gestation, experienced bleeding and missed abortion, at which time she visited the emergency room. The physician stated it was unclear if the patient was still on DEPAKOTE during the pregnancy. The reporting physician considered the events bleeding and missed abortion to be other important medical events. Additional information has been requested.
pt recv vax 29AUG95 & 11SEP devel small papulvesicular lesions on upper arms; no constitutional sx; rash spread to neck & second day but cleared p/third day
Information has been received from a female pharmacist of unknown age concerning herself. The patient's concurrent conditions, medical histories and concomitant therapies were not provided. On 22-SEP-2016, when the patient went to twist the cap off she inadvertently stuck herself with the needle after reconstituting the ZOSTAVAX (lot #, expiration date, dose and route were unknown) with it. Then she removed the needle and placed a new needle on the syringe to administer the full dose to an unspecified patient. No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
This spontaneous report was received from a pharmacist who is a 50 year (reported as currently in 50's) old female patient regarding herself. Patient's concurrent conditions included drug reactions/allergies to streptomycin. The patient's medical history included removal of lung lobe on an unspecified date when she was 22 years old due to pneumonic plaque. The pharmacist became indicated to receive PNEUMOVAX 23 as a result of her past medical history. On an unknown date the patient was vaccinated with PNEUMOVAX 23 (dose, frequency and route unspecified). Concomitant medications were not reported. The pharmacist stated that she had received 3 doses of PNEUMOVAX 23 prior to her 65 birthday. The pharmacist stated that after her last dose of PNEUMOVAX 23 on an unspecified date in 2004 she had suffered from more joint pain than usual after receiving a dose of PNEUMOVAX 23. She stated that whenever she had received a PNEUMOVAX 23 vaccine in the past on unspecified dates there was always discomfort at the injection site and she would feel tired after receiving the PNEUMOVAX 23. The patient sought medical attention. No treatment was given for the events. The outcome of the events was reported as recovered/resolved on an unknown date. The causality of the events with PNEUMOVAX 23 was not reported. Additional information has been requested.
Patient received vaccine on 9/4/2020, reported development of blistery rash on right upper back on 9/6/20 that was identified as varicella-zoster virus infection on 9/7/2020
chills; low grade fever; aches; nausea; vertigo; dizzy; hollow tunnel feeling; vibration feeling under skin; fatigue; brain fog; confusion; verbal errors; This is a spontaneous report from a contactable consumer (patient herself). A 48-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EW0151, expiration date: not reported), via an unspecified route of administration, administered in Arm Left on 02Apr2021 13:15 (age at the time of vaccination was 48-year-old) as dose 2, single for COVID-19 immunization in hospital. The patient's medical history was not reported. The patient's concomitant medications were not reported. Patient had no covid prior vaccination. Historical vaccine includedBNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EN6208, expiration date: not reported), via an unspecified route of administration, administered in the left arm on 13Mar2021 at 12:15 as dose 1, single for COVID-19 immunization. Patient had no other vaccine in four weeks. On 03Apr2021, the patient experienced chills, low grade fever, aches, nausea, vertigo, dizzy, hollow tunnel feeling, vibration feeling under skin, fatigue, brain fog, confusion, verbal errors. The patient underwent lab tests and procedures which included sars-cov-2 test was negative on 29Mar2021. Patient had no treatment for the events. Clinical outcome of the events was reported as not recovered.   No follow-up attempts are needed. No further information is expected.
On 2-11-08 pt walks in to clinic to show Lt arm.  Redness, warm to touch noted about 2 1/2 inches below injection site.  Pt states felt discomfort the night of injection given.  On (2/5/08) pt felt discomfort and took Tylenol & applied warm towel 3-5 min. at night.  On 2-6 & 2-7-08 also felt discomfort but also itchy.  On 2-8-08 pt noted redness & warm to touch below injection site only.  On 2-9 & 2-10-08 with redness & warm to touch.  On 2-11-08 redness decreased.  Pt applied hydrocortisone cream for itching.  On 2-12-08 redness & itching gone.  On 2-13-08 pt denies any complaint.  Denies numbness, tingling; good ROM; no distress voiced from pt.
Redness swelling, pain at injection site.  Patient/provider felt injection may have been given too low on arm.
SORENESS AND SWELLING, SLIGHT REDNESS LEFT ARM FROM ELBOW TO SHOULDER ~12 HRS AFTER RECEIVING PNEUMOVAX         IBUPROFEN AND COOL COMPRESS RECOMMENDED, CALL md IF SXS WORSEN
8 days after the injection a knot formed at the injection site, on the 9th day knot became larger, red  and hot to the touch. My physician recommended Benadryl and ice to injection site.
Myalgia of deltoid at vaccination site, initally improved, but patient developed URI, at that time pain has increased ever since. Patient currently on pain meds/anti-inflammatory with hopes this is localized reaction that will subside over time.
Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days; Date the vial was initially stored in the refrigerator was 28-Dec-2021/ stored in the fridge for more than 30 days.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 28-Dec-2021/ stored in the fridge for more than 30 days.) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033H21A) for COVID-19 vaccination.     Concurrent medical conditions included HIV disease (Patient was under treatment for this illness). Concomitant products included DOLUTEGRAVIR SODIUM, RILPIVIRINE HYDROCHLORIDE (JULUCA), BUPROPION HYDROCHLORIDE (WELLBUTRIN), ATORVASTATIN CALCIUM (LIPITOR), DOLUTEGRAVIR SODIUM (TIVICAY), SILDENAFIL and DARUNAVIR ETHANOLATE (PREZISTA) for an unknown indication.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Feb-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 28-Dec-2021/ stored in the fridge for more than 30 days.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 28-Dec-2021/ stored in the fridge for more than 30 days.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that the vial did not undergo any temperature excursions  HCP did not know if any treatment was given to the patient, as HCP did not know if the patient experienced any symptoms after vaccination.
Covid vaccine 1: flushing, red, itchy ears, tingling and itchy lips. Shortness of breath
patient experienced right sided face tingling and coughing. Patient given EpiPen x2 doses and 25 mg IM Bendryl. Patient transferred to ED by EMS.
Reporting because this staff member received a dose 1 vaccine for MODERNA at our clinic on 12/28/2020. Then upon receiving second MODERNA vaccine at our site on 1/25/2021, it was noticed in IIS that this staff member received a dose 1 of PFIZER at another clinic on 1/4/2021.
Pain and weakness  in left arm. Constant twitching of muscles in left arm for long periods of time. Pain in my toes to my fingernails. Lots of nerve pain. Feels like an inflammation around heart or chest cavity (that has mostly subsided at this time).
Multiple left supraclavicular lymph node enlargement. Tender to touch.   Started on 01/12/2021, has increased slightly.  On 01/18/2021, felt an additional lymph node.
101-102 began 7FEB-9FEB APAP not controlling temp; not eating well; 9DEC seen by MD; URI;
After receiving her immunization and while she was in the waiting area, pt stated she was feeling dizzy and had altered taste and was feeling cold. I applied a cold pack on her forehead as well as had her elevate her legs and lean her head against the wall. Her friend had already given her water. Her heart rate was elevated and she did say she was really nervous getting the immunization and that she did not want to get it but was forced to from work. My tech and I observed her for an additional 15 minutes with the cold pack and she stated she was feeling better and wanted to go home. We helped her stand and observed her. She stated she was feeling better and left with her friend supporting her.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 77-year-old male patient received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 28Apr2023 as dose 6 (booster), single (Lot number: GJ3268) at the age of 76 years, in right arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown), as dose 4 (booster), single (Batch/Lot number: unknown) and as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "hypertension" (unspecified if ongoing), notes: controlled with medication; "high cholesterol" (unspecified if ongoing), notes: controlled with medication. Concomitant medication(s) included: BENAZEPRIL, start date: May2010; ATORVASTATIN, start date: Jun2010, stop date: 20Sep2023. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2023, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Sep2023) Positive, notes: Treatment of Covid-19. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid from 21Sep2023 to 25Sep2023. Clinical course: The patient had no known allergies.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300316246 same reporter/patient, different drug/AE;